company background image
MXCT

MaxCyteAIM:MXCT Stock Report

Last Price

UK£5.30

Market Cap

UK£536.4m

7D

-7.8%

1Y

-20.9%

Updated

20 Jan, 2022

Data

Company Financials +
MXCT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MXCT Stock Overview

MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally.

MaxCyte Competitors

Thermo Fisher Scientific

NYSE:TMO

US$231.8b

Novartis

SWX:NOVN

CHF182.1b

Lonza Group

SWX:LONN

CHF48.8b

Bio-Rad Laboratories

NYSE:BIO

US$17.7b

Price History & Performance

Summary of all time highs, changes and price drops for MaxCyte
Historical stock prices
Current Share PriceUK£5.30
52 Week HighUK£12.35
52 Week LowUK£5.24
Beta1.04
1 Month Change-26.80%
3 Month Change-31.17%
1 Year Change-20.90%
3 Year Change186.49%
5 Year Change125.53%
Change since IPO592.81%

Recent News & Updates

Nov 17
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

MXCTGB Life SciencesGB Market
7D-7.8%-5.1%-1.0%
1Y-20.9%-6.4%8.3%

Return vs Industry: MXCT underperformed the UK Life Sciences industry which returned -6.4% over the past year.

Return vs Market: MXCT underperformed the UK Market which returned 8.3% over the past year.

Price Volatility

Is MXCT's price volatile compared to industry and market?
MXCT volatility
MXCT Average Weekly Movement10.0%
Life Sciences Industry Average Movement7.7%
Market Average Movement5.0%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.5%

Stable Share Price: MXCT is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: MXCT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
199865Doug Doerflerhttps://www.maxcyte.com

MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services.

MaxCyte Fundamentals Summary

How do MaxCyte's earnings and revenue compare to its market cap?
MXCT fundamental statistics
Market CapUS$732.08m
Earnings (TTM)-US$16.86m
Revenue (TTM)US$32.26m

22.7x

P/S Ratio

-43.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MXCT income statement (TTM)
RevenueUS$32.26m
Cost of RevenueUS$3.33m
Gross ProfitUS$28.93m
ExpensesUS$45.79m
Earnings-US$16.86m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.17
Gross Margin89.68%
Net Profit Margin-52.27%
Debt/Equity Ratio0%

How did MXCT perform over the long term?

See historical performance and comparison

Valuation

Is MaxCyte undervalued compared to its fair value and its price relative to the market?

2.77x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: MXCT (£5.3) is trading above our estimate of fair value (£0.09)

Significantly Below Fair Value: MXCT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MXCT is unprofitable, so we can't compare its PE Ratio to the European Life Sciences industry average.

PE vs Market: MXCT is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MXCT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MXCT is good value based on its PB Ratio (2.8x) compared to the GB Life Sciences industry average (4.2x).


Future Growth

How is MaxCyte forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-3.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MXCT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MXCT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MXCT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MXCT's revenue (23% per year) is forecast to grow faster than the UK market (4.8% per year).

High Growth Revenue: MXCT's revenue (23% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MXCT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has MaxCyte performed over the past 5 years?

-20.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MXCT is currently unprofitable.

Growing Profit Margin: MXCT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MXCT is unprofitable, and losses have increased over the past 5 years at a rate of 20.6% per year.

Accelerating Growth: Unable to compare MXCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MXCT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (68.7%).


Return on Equity

High ROE: MXCT has a negative Return on Equity (-6.38%), as it is currently unprofitable.


Financial Health

How is MaxCyte's financial position?


Financial Position Analysis

Short Term Liabilities: MXCT's short term assets ($269.5M) exceed its short term liabilities ($12.6M).

Long Term Liabilities: MXCT's short term assets ($269.5M) exceed its long term liabilities ($996.8K).


Debt to Equity History and Analysis

Debt Level: MXCT is debt free.

Reducing Debt: MXCT has no debt compared to 5 years ago when its debt to equity ratio was 98.1%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MXCT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: MXCT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 25.4% each year


Dividend

What is MaxCyte current dividend yield, its reliability and sustainability?

0.068%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MXCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MXCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MXCT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MXCT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MXCT's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Doug Doerfler (65 yo)

23.5yrs

Tenure

US$1,223,727

Compensation

Mr. Douglas Arthur Doerfler, also known as Doug, Founded MaxCyte, Inc. in July 1998 and has been its Chief Executive Officer and President since June 1999. Mr. Doerfler served senior corporate development...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD1.22M) is about average for companies of similar size in the UK market ($USD1.06M).

Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MXCT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: MXCT's board of directors are seasoned and experienced ( 10.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MXCT insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.1%.


Top Shareholders

Company Information

MaxCyte, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: MaxCyte, Inc.
  • Ticker: MXCT
  • Exchange: AIM
  • Founded: 1998
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: UK£536.374m
  • Shares outstanding: 101.20m
  • Website: https://www.maxcyte.com

Number of Employees


Location

  • MaxCyte, Inc.
  • 22 Firstfield Road
  • Suite 110
  • Gaithersburg
  • Maryland
  • 20878
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/20 21:17
End of Day Share Price2022/01/20 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.